CIDP, chronic inflammatory demyelinating polyneuropathy, is an
acquired immune-mediated inflammatory disorder of the
peripheral nerves characterized by gradually increasing
sensory loss and
weakness associated with
loss of reflexes.
CIDP results from
damage to the myelin, covering of the nerves. It can occur at
any age and is more frequent in men than women.
If untreated, 30% of CIDP patients will progress to wheelchair dependence. And early diagnosis and proper treatments can avoid disability in a significant extent.
According to some studies, the
progressive category of CIDP is more common than
relapsing-remitting one,
myelin and
axon are more likely to be all affected than the individual.
Moreover,
factors that
are not significantly associated with prognosis include:
- age
- course of disease
- sensory disturbance
- muscle strength
- tendon reflexes diminish
- autonomic nervous symptoms
- muscle atrophy
- cerebrospinal fluid protein content
The
risk factor for CIDP is
axonal involvement, and the
protective factor is
immunoglobulin therapy.
The prognosis of axonal involvement group is worse than the simple demyelinating group.
Keyword: prognosis of cidp patients.
